Clinical value of tumor markers SCCA,TPS,NSE and CYFERA21-1 detection in diagnosis of lung cancer / 国际检验医学杂志

ABSTRACT

Objective To explore the clinical value of tumor marker squamous cell carcinoma antigen(SCCA) ,tissue polypeptide specific antigen(TPS) ,neuron‐specific enolase(NSE) ,cytokeratin fragment 19(CYFRA21‐1) detections in the patient with lung cancer .Methods 70 patient with newly diagnosed lung cancer(including 26 cases of squamous cell carcinoma ,23 cases of adenocar‐cinoma and 21 cases of small cell carcinoma) ,40 cases of lung benign diseases and contemporaneous 30 individuals undergoing the physical examination were randomly selected as the lung cancer group ,lung benign disease group and healthy control group respec‐tively .Serum tumor markers of SCCA ,TPS ,NSE and CYFERA21‐1 were detected in all cases .Then the detection results were per‐formed the statistical analysis .Results The levels of SCCA ,TPS ,NSE and CYFERA21‐1 in the lung cancer group were significant‐ly higher than those in the lung benign diseases group and healthy control group ,the differences were statistically significant (P0 .05) .The combination detection of SCCA , TPS ,NSE and CYFERA21‐1 greatly increased the sensitivity and accuracy for diagnosing lung cancer .Conclusion The combina‐tion detection of SCCA ,TPS ,NSE and CYFERA21‐1 has very high clinical value for the diagnosis ,pathological typing and assisted clinical therapy of lung cancer .